P2906
Poly(ethylene glycol)
Hybri-Max™, mol wt 3,000-3,700, waxy solid, BioReagent, suitable for hybridoma
Synonym(s):
Polyethylene glycol, PEG
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Linear Formula:
H(OCH2CH2)nOH
CAS Number:
NACRES:
NA.75
PubChem Substance ID:
UNSPSC Code:
12161902
MDL number:
biological source
synthetic (organic)
Quality Level
grade
Hybri-Max™
sterility
autoclaved
product line
BioReagent
form
waxy solid
mol wt
3,000-3,700
technique(s)
cell culture | hybridoma: suitable
impurities
endotoxin, tested
SMILES string
C(CO)O
InChI
1S/C2H6O2/c3-1-2-4/h3-4H,1-2H2
InChI key
LYCAIKOWRPUZTN-UHFFFAOYSA-N
General description
Poly(ethylene glycol) (PEG) is a non-ionic hydrophilic polymer and is available in different molecular weights. It either exists in the form of a linear or branched structure. It aids in the purification and crystal growth of proteins and nucleic acids. PEG along with dextran is used to achieve an aqueous polymer two-phase system, which is essential for the purification of biological materials. It permits cell fusion through its interaction with the cell membrane.
Application
Poly(ethylene glycol) has been used in the production of monoclonal antibodies.
Recommended for cell fusion.
Recommended for cell fusion.
Legal Information
Hybri-Max is a trademark of Sigma-Aldrich Co. LLC
Still not finding the right product?
Explore all of our products under Poly(ethylene glycol)
Storage Class
11 - Combustible Solids
wgk
WGK 1
flash_point_f
281.5 °F - closed cup
flash_point_c
138.6 °C - closed cup
ppe
Eyeshields, Gloves, type N95 (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Extensive nuclear localization of alpha-synuclein in normal rat brain neurons revealed by a novel monoclonal antibody
Yu S, et al.
Neuroscience journal, 145(2), 539-555 (2007)
Harris JM
Poly(Ethylene Glycol) Chemistry: Biotechnical and Biomedical Applications (2013)
Agathe Dubuisson et al.
Cell death & disease, 10(2), 101-101 (2019-02-06)
Development of therapeutic antibodies in oncology has attracted much interest in the past decades. More than 30 of them have been approved and are being used to treat patients suffering from cancer. Despite encouraging results, and albeit most clinical trials